Research on Blood–Brain Barrier and Central Nervous System Drug Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 20 December 2024 | Viewed by 181
Special Issue Editors
Interests: blood–brain barrier; neurovascular unit; blood-retina barrier; drug transporters; brain drug delivery; SLC and ABC transporters; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute an original manuscript to our Special Issue on drug delivery to the blood–brain barrier (BBB) and central nervous system (CNS). Accumulating physiologically relevant amounts of a therapeutic within the CNS to treat many neurological conditions remains challenging. This Special Issue will highlight new advances in BBB delivery and the CNS accumulation of therapeutics for treating acute and chronic neurological disorders. Priority will be given to articles using particles and microbials to enhance drug delivery through the BBB and considering the accumulation of therapeutics in the CNS. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: engineering synthetic or naturally derived particles such as exosomes to cross the BBB, microbial-derived strategies for treating CNS diseases, and strategies designed to enhance the accumulation of therapeutics within the CNS post-BBB delivery.
We look forward to receiving your contributions.
Prof. Dr. Salvatore Cisternino
Dr. Benjamin J. Umlauf
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- blood–brain barrier (BBB)
- drug delivery
- nanoparticle
- exosome
- microbial factories
- central nervous system (CNS) accumulation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.